SEATTLE–(BUSINESS WIRE)– #airo–As Amtrak prepares to debut it’s new $8 billion Airo trainsets – SeaPort Airlines is offering an alternative that cuts the travel time by over half and requires no massive public investment of funds. “I love the train. But not if I have to get somewhere. Or by a certain time,” says SeaPort Airlines Founder and CEO Kent Craford. “SeaPort Airlines was founded to get the Pacific Northwest moving again, shortening the distance between our major cities, so you can leave hom
Author: sHq_LoGiNz
AURORA, Colo.–(BUSINESS WIRE)– #biotech–RefinedScience today announced a multi-institutional agreement that puts the Marsico Pancreatic Cancer Initiative on track to become the world’s largest multimodal single-cell pancreatic ductal adenocarcinoma (PDAC) dataset by the end of 2026, with contracted and partnered access to more than 2,000 consented pancreatic cancer samples from leading academic and industry sources. Pancreatic cancer is among the deadliest major cancers, in large part because the disea
VERNON HILLS, Ill.–(BUSINESS WIRE)–CDW (Nasdaq: CDW), the strategic end-to-end technology partner that turns customer ambition into outcomes, today announced that it has completed its previously announced acquisition of Lovelytics, a leading data and AI services firm and a member of the Databricks Brickbuilder Partner Network. The acquisition expands CDW’s Services & Solutions portfolio and will bring the Lovelytics capabilities to a broader set of customers. Lovelytics helps organization
GRAPEVINE, Texas–(BUSINESS WIRE)–On September 23, 2026, Southland Holdings, Inc. (NYSE American: SLND and SLND WS) (the “Company”) received notification (the “Notice”) from NYSE Regulation of the NYSE American LLC (“NYSE American”) that the Company is no longer in compliance with NYSE American’s continued listing standards. Specifically, the Notice states that the Company is not in compliance with the continued listing standards set forth in Sections 1003(a)(i) and 1003(a)(ii) of the NYSE Ame
NORWALK, Conn.–(BUSINESS WIRE)–Silgan to Release Third Quarter 2026 Earnings Results on October 29, 2026
MIAMI–(BUSINESS WIRE)–On September 25, 2026, the Fairholme Focused Income Fund (“FOCIX” or the “Fund”) distributed an Ordinary Income dividend of $0.05297 per share to shareholders of record as of September 24, 2026. The Fund’s Net Asset Value (“NAV”) was reduced by the amount of the distribution. The Record Date, Ex-Dividend Date, Payable Date, and Cents-Per-Share are as follows: THE FAIRHOLME FOCUSED INCOME FUND Distribution Type Record Date Ex-Dividend Date Payable Date Cents-Per-Share Ord
SAN JOSÉ, California–(BUSINESS WIRE)–NetApp® (NASDAQ: NTAP), la empresa de infraestructura de datos inteligente, anunció hoy su intención de adquirir PEAK:AIO, una empresa pionera en arquitectura de metadatos de próxima generación y sistemas de archivos paralelos de alto rendimiento. Se prevé que la adquisición prevista acelere la hoja de ruta de infraestructura de IA de NetApp al ampliar los servicios de metadatos y la innovación en espacios de nombres paralelos, diseñados para ayudar a las
TORONTO–(BUSINESS WIRE)–Generis Group is pleased to announce it has ranked #157 on the 2026 Report on Business magazine ranking of Canada’s Top Growing Companies, marking the fifth time the company has earned a place on The Globe and Mail’s annual ranking. Generis also ranked #6 in the Marketing category. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Generis earned its spot with three-year revenue growth of 167% from 2022 to 2025. “We’re incredibly prou
LOS ANGELES–(BUSINESS WIRE)– #ASTRO26–ASTRO 2026 presentations demonstrate role of genetics in predicting adverse events and response from radiation treatment.
SAN FRANCISCO–(BUSINESS WIRE)–Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will be featured in new data presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. Collectively, these studies expand the evidence supporting MMAI’s potential to deliver consistent, biologically meaningful insights across diverse patient populations and clinical settings. The findings carry implications for more personal